Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Ophthalmology
Respiratory & Allergy
Oncology: Solid Tumors
Hematology
Biosimilars
Global Health
Abbreviations
JakaviⓇ - JAK 1/2 inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT03491215 REACH4 (CINC424F12201)
Acute graft versus host disease
Phase 2
45
Measurement of PK parameters
Overall Response Rate (ORR)
Ruxolitinib
NCT03774082 REACH5 (CINC424G12201)
Chronic graft versus host disease
Phase 2
45
Overall Response Rate (ORR)
Ruxolitinib 5mg tablets / pediatric formulation
Pediatric patients with grade II-IV acute graft vs. host disease after allogeneic
hematopoietic stem cell transplantation
Pediatric subjects with moderate and severe chronic Graft vs. Host disease after
allogeneic stem cell transplantation
Target Patients
Read-out Milestone(s)
2023
Publication
TBD
129 Investor Relations | Q4 2021 Results
2023
TBD
NOVARTIS | Reimagining MedicineView entire presentation